Pharmacyclics LLC v. Alvogen Pine Brook LLC – Imbruvica® (Ibrutinib)

Start
Case Name: Pharmacyclics LLC v. Alvogen Pine Brook LLC, Civ. No. 19-434-CFC, 2024 WL 1885677 (D. Del. Apr. 30, 2024) (Connolly, J.) – Drug Product and Patent(s)-in-Suit: Imbruvica® (ibrutinib); U.S. Patents Nos. 8,008,309 (“the ’309 patent”), 8,754,090 (“the ’090 patent”), 9,655,857 (“the ’857 patent”), and 9,725,455 (“the ’455 patent”)….
By: Robins Kaplan LLP
Previous Story

Seattle Tech Week Takeaways: How Software Investors Fund the Right Fit

Next Story

NIST Releases Three Post-Quantum Cryptography Standards